# Ponatinib / Asciminib nella LMC – Report strategico quindicinale (ultimi 30 giorni)
_Generata il: 2026-03-01_

## Executive brief

**3 takeaway (cosa conta davvero):**
- Nel periodo emergono soprattutto temi su **Altro** (n=2).
- Secondo filone: **Resistenza / T315I / mutazioni** (n=2).
- Terzo filone: **Safety e comorbidità** (n=1).

**Watchlist (cosa tenere d’occhio):**
- Monitorare evoluzione su **Safety e comorbidità** (nuovi segnali/dati).
- Monitorare evoluzione su **Resistenza / T315I / mutazioni** (nuovi segnali/dati).

**Action list (cosa fare in pratica):**
- Rivedere/rafforzare **monitoraggio cardiovascolare e interazioni** (es. anticoagulanti) nei pazienti in TKI.
- Valutare criteri interni per **consolidamento / de-escalation / TFR** nei pazienti in deep response.
- Verificare percorso di **test mutazionale** e criteri di switch nelle resistenze (incl. T315I).

---

## Top 5 da leggere subito (ordinati per impatto)

### 1) Is asciminib an effective tyrosine kinase inhibitor for chronic myeloid leukemia patients with tyrosine kinase inhibitor resistance?
- **Impact score**: 12 | **Tipo**: Trial clinico
- **Focus clinico**: Resistenza / T315I / mutazioni, Safety e comorbidità
- PMID: 41724089 | 10.1016/j.htct.2026.106257
- Link PubMed: https://pubmed.ncbi.nlm.nih.gov/41724089/

- Tipo di studio/popolazione: Such a selective inhibitor offers an alternative treatment strategy for patients with chronic myeloid leukemia who have developed resistance to previous tyrosine kinase inhibitor therapies.
- Risultato chiave: Although asciminib demonstrates a superior safety profile, primarily characterized by a reduction in cardiovascular adverse events associated with prior tyrosine kinase inhibitors, its clinical significance extends further.
- Rilevanza clinica: It remains essential to continue research and clinical trials to enhance the therapeutic efficacy of asciminib and manage its associated side effects.

---

### 2) Dual Proteasome and Histone Deacetylase Inhibition Overcomes Tyrosine Kinase Inhibitor Resistance in Breakpoint Cluster Region: Abelson 1-Driven Leukaemia Cell Lines.
- **Impact score**: 5 | **Tipo**: Preclinico / laboratorio
- **Focus clinico**: Resistenza / T315I / mutazioni, Dose strategy / consolidamento
- PMID: 41696976 | 10.1111/jcmm.71053
- Link PubMed: https://pubmed.ncbi.nlm.nih.gov/41696976/

- Tipo di studio/popolazione: Resistance to tyrosine kinase inhibitors (TKIs) remains a major challenge in breakpoint cluster region (BCR)::Abelson 1 (ABL1)-driven leukaemias.
- Risultato chiave: Viability, cytotoxicity, and caspase-3/7 activity were assessed following single-agent treatment with asciminib, ponatinib, bortezomib, or panobinostat.
- Rilevanza clinica: Asciminib showed reduced potency in resistant models and a right-shifted dose-response curve in T315I cells, whereas ponatinib retained activity across BCR::ABL1 variants.

---

### 3) The Care and Cure of the Leukemias in 2026.
- **Impact score**: 1 | **Tipo**: Preclinico / laboratorio
- **Focus clinico**: Altro
- PMID: 41761287 | 10.1002/ajh.70247
- Link PubMed: https://pubmed.ncbi.nlm.nih.gov/41761287/

- Tipo di studio/popolazione: Currently, most leukemias are effectively treated with immunotherapies (highly effective monoclonal antibodies targeting CD19 [blinatumomab], or CD22 [inotuzumab ozogamicin]), BCR::ABL1 tyrosine kinase inhibitors (TKIs; e.g., dasatinib, ponatinib), Bruton TKIs (e.g., ibrutinib, acalabrutinib), BCL-2 inhibitors (venetoclax), IDH1/2 inhibitors (ivosidenib, olutasidenib, and enasidenib), FLT3 inhibitors (e.g., midostaurin, quizartinib, and gilteritinib), menin inhibitors (revumenib, ziftomenib), and chimeric antigen receptor T-cell therapies.
- Risultato chiave: The BCR::ABL1 TKIs resulted in normal life expectancy in chronic myeloid leukemia.
- Rilevanza clinica: Notable advances have also been made in AML with targeted therapies, although some subsets (older/unfit patients for intensive chemotherapy, complex karyotype, TP53-mutated, KMT2A-rearranged, and treated secondary AML) still have unfavorable outcomes.

---

### 4) Secondary Chronic Myeloid Leukemia in the Blast Phase With Mixed Phenotype After Radiation Therapy: A Case Report.
- **Impact score**: 1 | **Tipo**: Preclinico / laboratorio
- **Focus clinico**: Altro
- PMID: 41737783 | 10.1002/jha2.70249
- Link PubMed: https://pubmed.ncbi.nlm.nih.gov/41737783/

- Tipo di studio/popolazione: A 55-year-old woman underwent hysterectomy and pelvic radiation for cervical cancer, which remains in remission.
- Risultato chiave: Following induction therapy, sequential therapy with blinatumomab and ponatinib achieved qualitatively PCR-negative minor <i>BCR::ABL1</i> transcripts, indicating that residual transcripts below the qualitative assay's detection limit were undetectable.
- Rilevanza clinica: She received an allogeneic bone marrow transplant and remains well with PCR-negative minor <i>BCR::ABL1</i> at 15 months after transplantation.

---

## Evidenze per domande cliniche

### Altro (2)

#### The Care and Cure of the Leukemias in 2026.
- Impact score: 1 | Tipo: Preclinico / laboratorio
- PMID: 41761287 | 10.1002/ajh.70247
- Link PubMed: https://pubmed.ncbi.nlm.nih.gov/41761287/
- Open Access (Europe PMC/PMC): non rilevato

**Mini-riassunto (da abstract, estrattivo):**
- Tipo di studio/popolazione: Currently, most leukemias are effectively treated with immunotherapies (highly effective monoclonal antibodies targeting CD19 [blinatumomab], or CD22 [inotuzumab ozogamicin]), BCR::ABL1 tyrosine kinase inhibitors (TKIs; e.g., dasatinib, ponatinib), Bruton TKIs (e.g., ibrutinib, acalabrutinib), BCL-2 inhibitors (venetoclax), IDH1/2 inhibitors (ivosidenib, olutasidenib, and enasidenib), FLT3 inhibitors (e.g., midostaurin, quizartinib, and gilteritinib), menin inhibitors (revumenib, ziftomenib), and chimeric antigen receptor T-cell therapies.
- Risultato chiave: The BCR::ABL1 TKIs resulted in normal life expectancy in chronic myeloid leukemia.
- Rilevanza clinica: Notable advances have also been made in AML with targeted therapies, although some subsets (older/unfit patients for intensive chemotherapy, complex karyotype, TP53-mutated, KMT2A-rearranged, and treated secondary AML) still have unfavorable outcomes.

---

#### Secondary Chronic Myeloid Leukemia in the Blast Phase With Mixed Phenotype After Radiation Therapy: A Case Report.
- Impact score: 1 | Tipo: Preclinico / laboratorio
- PMID: 41737783 | 10.1002/jha2.70249
- Link PubMed: https://pubmed.ncbi.nlm.nih.gov/41737783/
- Open Access (Europe PMC/PMC): sì (PMC12928080)

**Mini-riassunto (da abstract, estrattivo):**
- Tipo di studio/popolazione: A 55-year-old woman underwent hysterectomy and pelvic radiation for cervical cancer, which remains in remission.
- Risultato chiave: Following induction therapy, sequential therapy with blinatumomab and ponatinib achieved qualitatively PCR-negative minor <i>BCR::ABL1</i> transcripts, indicating that residual transcripts below the qualitative assay's detection limit were undetectable.
- Rilevanza clinica: She received an allogeneic bone marrow transplant and remains well with PCR-negative minor <i>BCR::ABL1</i> at 15 months after transplantation.

**Riassunto aggiuntivo (full text Open Access, estrattivo):**
- Metodi (full text OA): non riportato.
- Risultato principale (full text OA): non riportato.
- Dettaglio utile (full text OA): non riportato.
- Messaggio clinico (full text OA): One study indicated that the standardized incidence ratio of CML is not increased in patients who receive radiation therapy alone for cervical cancer [18].

---

### Resistenza / T315I / mutazioni (2)

#### Is asciminib an effective tyrosine kinase inhibitor for chronic myeloid leukemia patients with tyrosine kinase inhibitor resistance?
- Impact score: 12 | Tipo: Trial clinico
- PMID: 41724089 | 10.1016/j.htct.2026.106257
- Link PubMed: https://pubmed.ncbi.nlm.nih.gov/41724089/
- Open Access (Europe PMC/PMC): sì (PMC12936483)

**Mini-riassunto (da abstract, estrattivo):**
- Tipo di studio/popolazione: Such a selective inhibitor offers an alternative treatment strategy for patients with chronic myeloid leukemia who have developed resistance to previous tyrosine kinase inhibitor therapies.
- Risultato chiave: Although asciminib demonstrates a superior safety profile, primarily characterized by a reduction in cardiovascular adverse events associated with prior tyrosine kinase inhibitors, its clinical significance extends further.
- Rilevanza clinica: It remains essential to continue research and clinical trials to enhance the therapeutic efficacy of asciminib and manage its associated side effects.

**Riassunto aggiuntivo (full text Open Access, estrattivo):**
- Metodi (full text OA): non riportato.
- Risultato principale (full text OA): non riportato.
- Dettaglio utile (full text OA): non riportato.
- Messaggio clinico (full text OA): A primary advantage of asciminib is its ability to circumvent the resistance and adverse events associated with traditional TKIs, particularly in patients with advanced-stage CML.

---

#### Dual Proteasome and Histone Deacetylase Inhibition Overcomes Tyrosine Kinase Inhibitor Resistance in Breakpoint Cluster Region: Abelson 1-Driven Leukaemia Cell Lines.
- Impact score: 5 | Tipo: Preclinico / laboratorio
- PMID: 41696976 | 10.1111/jcmm.71053
- Link PubMed: https://pubmed.ncbi.nlm.nih.gov/41696976/
- Open Access (Europe PMC/PMC): sì (PMC12908417)

**Mini-riassunto (da abstract, estrattivo):**
- Tipo di studio/popolazione: Resistance to tyrosine kinase inhibitors (TKIs) remains a major challenge in breakpoint cluster region (BCR)::Abelson 1 (ABL1)-driven leukaemias.
- Risultato chiave: Viability, cytotoxicity, and caspase-3/7 activity were assessed following single-agent treatment with asciminib, ponatinib, bortezomib, or panobinostat.
- Rilevanza clinica: Asciminib showed reduced potency in resistant models and a right-shifted dose-response curve in T315I cells, whereas ponatinib retained activity across BCR::ABL1 variants.

**Riassunto aggiuntivo (full text Open Access, estrattivo):**
- Metodi (full text OA): For single‐agent dose–response experiments, cells were treated with 10‐fold serial dilutions ranging from 0 to 1 μM for asciminib and ponatinib and from 0 to 100 nM for bortezomib and panobinostat.
- Risultato principale (full text OA): Asciminib is a STAMP inhibitor approved for CML [18].
- Dettaglio utile (full text OA): (A) CML cell lines (K562, K562 PR, K562 IR, Ba/F3 asc‐R, Ba/F3 PR, Ba/F3 BCR::ABL, and Ba/F3 T315I) were exposed to asciminib (0–1 μM) for 72 h, and cell viability was measured using the Cell Counting Kit‐8 (CCK‐8) assay.
- Messaggio clinico (full text OA): A prior clinical trial explored the combination of a proteasome inhibitor with an HDAC inhibitor in a phase I dose‐escalation study involving belinostat and bortezomib in adult patients with acute leukaemia, myelodysplastic syndromes, or blast‐crisis CML [27].

---

### Safety e comorbidità (1)

#### Is asciminib an effective tyrosine kinase inhibitor for chronic myeloid leukemia patients with tyrosine kinase inhibitor resistance?
- Impact score: 12 | Tipo: Trial clinico
- PMID: 41724089 | 10.1016/j.htct.2026.106257
- Link PubMed: https://pubmed.ncbi.nlm.nih.gov/41724089/
- Open Access (Europe PMC/PMC): sì (PMC12936483)

**Mini-riassunto (da abstract, estrattivo):**
- Tipo di studio/popolazione: Such a selective inhibitor offers an alternative treatment strategy for patients with chronic myeloid leukemia who have developed resistance to previous tyrosine kinase inhibitor therapies.
- Risultato chiave: Although asciminib demonstrates a superior safety profile, primarily characterized by a reduction in cardiovascular adverse events associated with prior tyrosine kinase inhibitors, its clinical significance extends further.
- Rilevanza clinica: It remains essential to continue research and clinical trials to enhance the therapeutic efficacy of asciminib and manage its associated side effects.

**Riassunto aggiuntivo (full text Open Access, estrattivo):**
- Metodi (full text OA): non riportato.
- Risultato principale (full text OA): non riportato.
- Dettaglio utile (full text OA): non riportato.
- Messaggio clinico (full text OA): A primary advantage of asciminib is its ability to circumvent the resistance and adverse events associated with traditional TKIs, particularly in patients with advanced-stage CML.

---

### Dose strategy / consolidamento (1)

#### Dual Proteasome and Histone Deacetylase Inhibition Overcomes Tyrosine Kinase Inhibitor Resistance in Breakpoint Cluster Region: Abelson 1-Driven Leukaemia Cell Lines.
- Impact score: 5 | Tipo: Preclinico / laboratorio
- PMID: 41696976 | 10.1111/jcmm.71053
- Link PubMed: https://pubmed.ncbi.nlm.nih.gov/41696976/
- Open Access (Europe PMC/PMC): sì (PMC12908417)

**Mini-riassunto (da abstract, estrattivo):**
- Tipo di studio/popolazione: Resistance to tyrosine kinase inhibitors (TKIs) remains a major challenge in breakpoint cluster region (BCR)::Abelson 1 (ABL1)-driven leukaemias.
- Risultato chiave: Viability, cytotoxicity, and caspase-3/7 activity were assessed following single-agent treatment with asciminib, ponatinib, bortezomib, or panobinostat.
- Rilevanza clinica: Asciminib showed reduced potency in resistant models and a right-shifted dose-response curve in T315I cells, whereas ponatinib retained activity across BCR::ABL1 variants.

**Riassunto aggiuntivo (full text Open Access, estrattivo):**
- Metodi (full text OA): For single‐agent dose–response experiments, cells were treated with 10‐fold serial dilutions ranging from 0 to 1 μM for asciminib and ponatinib and from 0 to 100 nM for bortezomib and panobinostat.
- Risultato principale (full text OA): Asciminib is a STAMP inhibitor approved for CML [18].
- Dettaglio utile (full text OA): (A) CML cell lines (K562, K562 PR, K562 IR, Ba/F3 asc‐R, Ba/F3 PR, Ba/F3 BCR::ABL, and Ba/F3 T315I) were exposed to asciminib (0–1 μM) for 72 h, and cell viability was measured using the Cell Counting Kit‐8 (CCK‐8) assay.
- Messaggio clinico (full text OA): A prior clinical trial explored the combination of a proteasome inhibitor with an HDAC inhibitor in a phase I dose‐escalation study involving belinostat and bortezomib in adult patients with acute leukaemia, myelodysplastic syndromes, or blast‐crisis CML [27].

---
